

**AMENDMENTS TO THE DRAWINGS**

Submitted herewith are one set (19 sheets, Figures 1a, 1b, 1c, 1d, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 4a, 5, 6a, 6b, 7a, 7b, 7c and 7d) of black and white drawings and three sets (2 sheets, Figures 4b and 4c) of color photos to replace the original drawings previously filed in the above-identified patent application.

In the substitute Figures 1c and 1d, appropriate SEQ ID NOS: have been inserted according to the requirements under 37 C.F.R. §§ 1.821-1.825. The quality of the remaining black and white figures has been improved. No new matter has been introduced by the amendments.

Originally filed black and white Figures 4b and 4c are herein replaced with the color photos. Accordingly, attached hereto is a "Petition for Acceptance of Color Photographs" accompanied by three (3) sets of the color photographs (*i.e.*, Figures 4b and 4c). No new matter has been introduced by the submission of the color photos.

**AMENDMENTS TO THE SEQUENCE LISTING**

Submitted herewith is a substitute Sequence Listing in which the two nucleotide sequences (SEQ ID NOS:8 and 9) appearing in Figure 1c and the four nucleotide sequences (SEQ ID NOS:10-13) appearing in Figure 1d have been added. No new matter has been introduced by the amendments.


Applicants attach hereto a "Submission of Substitute Sequence Listing and Statement under 37 C.F.R. §§ 1.821-1.825" accompanied by the substitute Sequence Listing in paper form and computer readable form (CRF).

**REMARKS**

Please consider the present application in view of the above amendments.

Dated: December 11, 2006

Respectfully submitted,

By   
Edward A. Meilman

Registration No.: 24,735  
DICKSTEIN SHAPIRO MORIN & OSHINSKY  
LLP  
1177 Avenue of the Americas  
New York, New York 10036-2714  
(212) 835-1400  
Attorneys for Applicants

IY/CEM/mgs

- Attachments:
1. Replacement black and white drawings (19 sheets);
  2. Petition for Acceptance of Color Photographs;
  3. Three sets (2 sheets each) of color photos (Figures 4b and 4c);
  4. Submission of Substitute Sequence Listing and Statement under 37 C.F.R. §§ 1.821-1.825; and
  5. Sequence Listing in paper form and CFR.